Scientific article

Cannabinoïdes médicaux dans les douleurs chroniques : aspects pharmacologiques

Published inRevue médicale suisse, vol. 11, no. 480, p. 1390,1392-1394
Publication date2015

In Switzerland, medical cannabinoids can be prescribed under compassionate use after special authorization in justified indications such as refractory pain. Evidence of efficacy in pain is limited and the clinical benefit seems to be modest. Their drug-drug interactions (DDI) profile is poorly documented. Cytochromes P450 (CYP) 2C9 and 3A4 are involved in the metabolism of tetrahydrocannabinol and cannabidiol, which implies possible DDI with CYP450 inhibitor and inducer, such as anticonvulsivants and HIV protease inhibitors, which may be prescribed in patients with neuropathic pain.

  • Cannabinoids/pharmacology/therapeutic use
  • Chronic Pain/drug therapy
  • Drug Interactions
  • Humans
  • Medical Marijuana/pharmacology/therapeutic use
  • Switzerland
  • Treatment Outcome
Citation (ISO format)
ING LORENZINI, Kuntheavy et al. Cannabinoïdes médicaux dans les douleurs chroniques : aspects pharmacologiques. In: Revue médicale suisse, 2015, vol. 11, n° 480, p. 1390,1392–1394.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation12/11/2015 3:34:00 PM
First validation12/11/2015 3:34:00 PM
Update time03/14/2023 11:59:08 PM
Status update03/14/2023 11:59:08 PM
Last indexation10/19/2023 12:26:02 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack